C07K 14/70503
Immunoglobulin superfamily
Official title: {Immunoglobulin superfamily}
C07K14/70503 (Immunoglobulin superfamily) appears on 6,238 US grants and 12,126 published applications in this corpus.
Search patents in C07K- Granted patents
- 6,238
- Published applications
- 12,126
- Assignees
- 2,977
- Inventors
- 16,196
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 3 | 0 |
| 1990 | 7 | 0 |
| 1991 | 7 | 0 |
| 1992 | 18 | 0 |
| 1993 | 27 | 0 |
| 1994 | 20 | 0 |
| 1995 | 23 | 0 |
| 1996 | 63 | 0 |
| 1997 | 91 | 0 |
| 1998 | 134 | 0 |
| 1999 | 143 | 0 |
| 2000 | 127 | 0 |
| 2001 | 90 | 10 |
| 2002 | 81 | 162 |
| 2003 | 79 | 233 |
| 2004 | 59 | 184 |
| 2005 | 59 | 152 |
| 2006 | 87 | 144 |
| 2007 | 82 | 110 |
| 2008 | 85 | 127 |
| 2009 | 64 | 157 |
| 2010 | 83 | 132 |
| 2011 | 81 | 162 |
| 2012 | 96 | 149 |
| 2013 | 84 | 149 |
| 2014 | 97 | 162 |
| 2015 | 106 | 201 |
| 2016 | 122 | 303 |
| 2017 | 142 | 420 |
| 2018 | 210 | 550 |
| 2019 | 339 | 786 |
| 2020 | 444 | 986 |
| 2021 | 456 | 1172 |
| 2022 | 509 | 1278 |
| 2023 | 494 | 1202 |
| 2024 | 600 | 1281 |
| 2025 | 613 | 1111 |
| 2026 | 410 | 803 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C07K 14/7051T-cell receptor -cd3 complex3,229
- C07K 14/70539Mhc-molecules1,276
- C07K 14/70521Cd28, cd1521,176
- C07K 14/70517Cd8784
- C07K 14/70532B7 molecules485
- C07K 14/70535Fc-receptors407
- C07K 14/70514Cd4373
- C07K 14/70525Icam molecules115
All 11 subgroupsShow fewer
Recent patents
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2Cellectis
- Anti-Nectin-4 antibody, conjugate including the same, and application thereof6 Oct 2026US 12,753,230 B2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Fusion protein comprising anti-CD3 single domain antibody, exosomal protein CD63 and RNA binding protein, and uses thereof6 Oct 2026US 12,753,232 B1China Medical University Hospital
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Cd28h domain-containing chimeric antigen receptors and methods of use8 Oct 2026US 2026/0306544 A1The United States of America, as represented by the Secretary, Dept. of Health and Human Services
- Timp3-derived teipp neoantigens and uses thereof8 Oct 2026US 2026/0306599 A1
- Chimeric receptors8 Oct 2026US 2026/0306631 A1St. Jude Children?S Research Hospital
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998